Health Care·Life Sciences Tools & Services·$2.2B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.25 | N/A | -15.21% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.25 | N/A | -15.21% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concern about the ongoing market conditions affecting performance. They did not provide any forward-looking guidance.
Management did not provide specific guidance for future quarters.
The company acknowledged challenges in the current market environment.
This earnings report indicates that Adaptive Biotechnologies is facing challenges, as evidenced by the missed EPS target. The stock's slight decline of 0.16% suggests that investors may be cautious following the results. The lack of revenue data and forward guidance adds to the uncertainty surrounding the company's future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BLOOM ENERGY CORP Class A
May 11, 2020